Scarica l'app Stockscreener
1.07
4.46%
-0.05
Dopo l'orario di chiusura:
1.12
0.05
+4.67%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.12
Aprire:
$1.08
Volume 24 ore:
185.36K
Relative Volume:
1.19
Capitalizzazione di mercato:
$16.88M
Reddito:
-
Utile/perdita netta:
$-52.53M
Rapporto P/E:
-0.2923
EPS:
-3.66
Flusso di cassa netto:
$-39.93M
1 W Prestazione:
+9.09%
1M Prestazione:
+18.89%
6M Prestazione:
-11.57%
1 anno Prestazione:
-33.54%
Intervallo 1D:
$1.06
$1.23
Intervallo di 1 settimana:
$0.98
$1.23
Portata 52W:
$0.8531
$3.10
Unity Biotechnology Inc Stock (UBX) Company Profile
Nome
Unity Biotechnology Inc
Settore
Industria
Telefono
(650) 416-1192
Indirizzo
285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA
Confronta UBX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
UBX
Unity Biotechnology Inc
|
1.07 | 16.88M | 0 | -52.53M | -39.93M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Unity Biotechnology Inc Stock (UBX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-22 | Iniziato | Rodman & Renshaw | Buy |
| 2023-11-16 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2022-01-04 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2021-11-10 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-06-28 | Aggiornamento | Citigroup | Sell → Buy |
| 2021-06-07 | Iniziato | H.C. Wainwright | Buy |
| 2021-02-16 | Downgrade | Citigroup | Neutral → Sell |
| 2020-08-18 | Downgrade | Citigroup | Buy → Neutral |
| 2020-08-18 | Downgrade | Mizuho | Buy → Neutral |
| 2020-08-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-08-17 | Downgrade | ROTH Capital | Buy → Neutral |
| 2020-07-28 | Iniziato | ROTH Capital | Buy |
| 2019-12-12 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-03-07 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-07 | Iniziato | Mizuho | Buy |
| 2018-05-29 | Iniziato | Citigroup | Buy |
| 2018-05-29 | Iniziato | Goldman | Neutral |
| 2018-05-29 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Unity Biotechnology Inc Borsa (UBX) Ultime notizie
South San Francisco biotech company lays off entire workforce, including CEO - KRON4
Bay Area biotech company lays off every single worker, including CEO - SFGATE
Finance Watch: Unity Lays Off All Employees As It Evaluates Alternatives - insights.citeline.com
UNITY Biotechnology (UBX) Reports Promising 36-Week Results from ASPIRE Trial | UBX Stock News - GuruFocus
Unity Biotechnology Explores Strategic Alternatives Post-ASPIRE Study - TipRanks
UNITY Biotechnology Estimates $3.7 Million Expenses For Reduction In Force - marketscreener.com
UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate Updates - The Manila Times
UNITY Biotechnology Announces Complete 36-Week Results from - GlobeNewswire
UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of ... - Bluefield Daily Telegraph
UNITY's New DME Treatment Rivals Aflibercept in Phase 2b Trial, Company Explores Strategic Options - Stock Titan
UNITY Biotechnology to Present 36-Week Data from ASPIRE Phase 2B Study at ARVO 2025 Annual Meeting - Nasdaq
UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting - GlobeNewswire
UNITY Biotechnology tanks after failing to meet goal in eye disorder treatment trial - MSN
Chardan Capital Brokers Decrease Earnings Estimates for UBX - Defense World
Form 8-KCurrent report - ADVFN
HC Wainwright Issues Positive Outlook for UBX Earnings - Defense World
HC Wainwright Reiterates “Buy” Rating for Unity Biotechnology (NASDAQ:UBX) - Defense World
Chardan Capital Reaffirms “Buy” Rating for Unity Biotechnology (NASDAQ:UBX) - Defense World
Unity Biotechnology Reports Q1 2025 Financials and Study Updates - TipRanks
H.C. Wainwright maintains $4 target on Unity Biotech stock - Investing.com Australia
Unity Biotechnology (UBX) Reports $16.9M in Cash, Prepares for F - GuruFocus
H.C. Wainwright maintains $4 target on Unity Biotech stock By Investing.com - Investing.com Nigeria
UNITY Biotechnology (UBX) Shows Promise with Senolytic UBX1325 i - GuruFocus
UNITY Biotechnology Announces Publication in NEJM Evidence - GlobeNewswire
Revolutionary DME Drug Maintains Vision Improvement for 12 Months After Just One Dose, NEJM Study Shows - Stock Titan
UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates | UBX Stock News - GuruFocus
UNITY Biotechnology Reports Q1 2025 Financial Results and ASPIRE Study Data on UBX1325 for Diabetic Macular Edema - Nasdaq
Unity Biotechnology, Inc. SEC 10-Q Report - TradingView
UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates - GlobeNewswire
UNITY's Eye Disease Drug Matches Standard Treatment at 36 Weeks: Key Trial Results Revealed - Stock Titan
Unity Biotechnology stock hits 52-week low at $0.94 By Investing.com - Investing.com Canada
Unity Biotechnology stock hits 52-week low at $0.94 - Investing.com
Unity Biotechnology CFO Lynne Sullivan sells $22,523 in stock By Investing.com - Investing.com Australia
Unity Biotechnology CFO Lynne Sullivan sells $22,523 in stock - Investing.com
Unity Biotechnology Executives Sell Shares for Tax Obligations - TradingView
HC Wainwright Has Pessimistic Outlook of UBX FY2026 Earnings - The AM Reporter
What is HC Wainwright’s Estimate for UBX FY2026 Earnings? - Defense World
Unity Biotechnology (NASDAQ:UBX) Price Target Lowered to $4.00 at Chardan Capital - Defense World
H.C. Wainwright cuts Unity Biotechnology target to $4; keeps buy rating - Investing.com Australia
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study - MSN
Unity Biotechnology price target lowered to $4 from $6 at Chardan - TipRanks
H.C. Wainwright cuts Unity Biotechnology target to $4; keeps buy rating By Investing.com - Investing.com South Africa
UNITY Biotechnology tanks on mixed results for eye disease drug - The Pharma Letter
Mizuho maintains Unity Biotechnology Outperform rating By Investing.com - Investing.com South Africa
Chardan Cuts Price Target on Unity Biotechnology to $4 From $6, Keeps Buy Rating - Marketscreener.com
Mizuho maintains Unity Biotechnology Outperform rating - Investing.com India
Unity Biotechnology (NASDAQ:UBX) Price Target Cut to $4.00 by Analysts at HC Wainwright - Defense World
UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE - EIN News
Sector Update: Health Care Stocks Rise Late Afternoon - TradingView
Sector Update: Health Care - TradingView
Unity Biotechnology Shares Decline After Diabetic Edema Treatment Misses Primary Endpoint - Marketscreener.com
Unity Biotechnology Inc Azioni (UBX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.39%
3.66%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):